Latest Paresthesia treatment Companies Updates:
Dec 2023
Nevro Corporation Launched their Senza® spinal cord stimulation (SCS) system with new features for personalized paresthesia treatment, offering targeted pain relief and symptom management.Partnered with pain management clinics and research institutions to expand access to SCS therapy for paresthesia patients.
Boston Scientific Corporation Received FDA approval for their Veritasi™ SCS system, featuring MRI compatibility and advanced programming capabilities for treating neuropathic pain and paresthesia.Focused on developing minimally invasive and patient-friendly treatment options for chronic pain conditions.
Abbott Laboratories Presented positive Phase III data on their spinal cord stimulation device for the treatment of diabetic peripheral neuropathy, offering potential relief for a large patient population.Collaborated with healthcare providers to improve diagnosis and management of diabetic nerve damage.
Baxter International Developed new formulations of topical lidocaine and capsaicin patches for local pain relief and management of paresthesia symptoms.Focused on providing affordable and accessible treatment options for patients with diverse pain conditions.
Medtronic Introduced their Stimwave® SCS system with advanced stimulation patterns and programming tools for more effective and individualized paresthesia treatment.Partnered with patient advocacy groups to raise awareness about pain management options for paresthesia.
List of Paresthesia treatment Key companies in the market
- Medtronic (UK)
- Omron Healthcare, Inc. (US)
- Boston Scientific Corporation (US)
- Stimwave LLC, (US)
- Nevro Corp. (US)
- Cyberonics, Inc. (US)
- EnteroMedics Inc. (US)
- St. Jude Medical, LLC. (US)
- Bio-Medical Research Ltd. (UK)
- Baxter (US)
- Stryker (US)
- GlaxoSmithKline plc.(UK).